Alliance/CALGB 80802: Impact of hepatitis C (HCV) on doxorubicin (DO) + sorafenib (S) versus S in patients (pts) with advanced hepatocellular carcinoma (aHCC).

Imane El-Dika,Susan Geyer,Andrew B. Nixon,Federico Innocenti,Qian Shi,Sawyer B. Jacobson,Amin Yaqubie,Juan C. Lopez,Binhui Huang,Yi-Wei Tang,Yujia Wen,Lawrence H. Schwartz,Monica M. Bertagnolli,Jeffrey A. Meyerhardt,Eileen M. O’Reilly,Alan P. Venook,Ghassan K. Abou-Alfa

Alliance/CALGB 80802: Impact of hepatitis C (HCV) on doxorubicin (DO) + sorafenib (S) versus S in patients (pts) with advanced hepatocellular carcinoma (aHCC).

2021

Imane El-Dika
Susan Geyer
Andrew B. Nixon
Federico Innocenti
Qian Shi
Sawyer B. Jacobson
Amin Yaqubie
Juan C. Lopez
Binhui Huang
Yi-Wei Tang
Yujia Wen
Lawrence H. Schwartz
Monica M. Bertagnolli
Jeffrey A. Meyerhardt
Eileen M. O’Reilly
Alan P. Venook
Ghassan K. Abou-Alfa

325Background: Alliance/CALGB 80802 randomized phase III trial evaluated DO+S vs. S in pts with aHCC, and showed no improvement in median OS. Multi-drug resistant pathway mitigation by the Ras/Raf/...

Keywords:

Hepatitis C
Internal medicine
Oncology
in patient
Doxorubicin
Hepatocellular carcinoma
Sorafenib
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations